Conclusion of non-exclusive drug discount agreement for Oxycodone/Naloxone
Original notice title
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Oxycodon/Naloxon (ATC-Code nach WHO: N02AA55)
Opportunity Score
Why this score?
Opportunity
10 / 100
Complexity
20 / 100
Risk factors
The XML change notice confirms the procedure ended on 30.09.2026 due to an exclusive agreement. Participation after tha...
No minimum purchase volumes; actual revenue depends on unpredictable prescription patterns.
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications
Tender facts
- Contracting authority
- AOK PLUS - Die Gesundheitskasse für Sachsen und Thürigen
- Country
- Germany
- CPV
- 33600000 - Pharmaceutical products
- Deadline
- Mar 31, 2027
Overview
Weak opportunityKey Facts
- Framework procurement
- Supplies contract
- 1 lot
- Duration until Mar 2027
- Supply of Oxycodone/Naloxone pharmaceutical products under non-exclusive discount agreements.
- Agreement under §130a Abs. 8 SGB V via open-house model.
Show full summary
This is an open-house model for non-exclusive drug discount agreements for Oxycodone/Naloxone (ATC N02AA55) with AOK PLUS. The procedure is not a public procurement under the directive but published for transparency. Key conflict: the XML change notice indicates the procedure ended early as of 30.09.2026 due to an exclusive agreement, while the structured data shows a deadline of 31.03.2027. No estimated value is provided. No procurement documents were analyzed beyond the notice.
Risks
The XML change notice confirms the procedure ended on 30.09.2026 due to an exclusive agreement. Participation after tha...
No minimum purchase volumes; actual revenue depends on unpredictable prescription patterns.
Analysis may be incomplete
Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.
Key Requirements
Technical
- Must be a pharmaceutical entrepreneur as per §4 Abs. 18 AMG for the offered drugs.
- Confidentiality: absolute secrecy regarding the content of the agreement and discount rates.
Eligibility
- Submit self-declarations: no exclusion grounds (§§123,124 GWB) and compliance with Russia sanctions (EU Reg. 833/2014).
Buyer
Location
Dresden, DEU
Website
Buyer profile
Identifier
DE256878834
Activity
Health
Lots (1)
LOT-0001
Conclusion of non-exclusive drug discount agreement for Oxycodone/Naloxone
Non-exclusive discount agreement for the active ingredient Oxycodone/Naloxone (ATC N02AA55). Open-house model with no minimum volume guaranteed. Performance in Dresden, Germany.
Location
Duration
Category
Deadline
Award details
Siehe Kurzbeschreibung
Show original TED data
Original lot title
Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Oxycodon/Naloxon (ATC-Code nach WHO: N02AA55)
Original TED description
Siehe Kurzbeschreibung
Procurement Details
- Publication date
- 03 Jun 2026
- Languages
- German
Reference metadata
- Legal basis
- 32014L0024
Reference IDs
- Tender ID
- 383818-2026
Documents (1)
Similar tenders
Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)
Germany – Pharmaceutical products – Abschluss nicht-exklusiver Rabattvereinbarungen nach § 130a Abs. 8 SGB V zu den genannten Wirkstoffen mit Abschlussmöglichkeit im Rahmen des sogenannten Open-House-Verfahrens.
Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta
Opportunity Score
Why this score?
Opportunity
10 / 100
Complexity
20 / 100
Risk factors
The XML change notice confirms the procedure ended on 30.09.2026 due to an exclusive agreement. Participation after tha...
No minimum purchase volumes; actual revenue depends on unpredictable prescription patterns.
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications